IP Library › Granted Patent US 7,935,791
Granted Patent B2
US 7,935,791 · App. 11/958,099 · Granted May 3, 2011

Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases

Assignee: Genentech, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,935,791
App. No.
11/958,099
Granted
May 3, 2011
Kind
B2
Abstract

The present invention relates to antagonist antibodies that specifically bind to Notch 3 and inhibit its activation. The present invention includes antibodies binding to a conformational epitope comprising the first Lin12 domain and the second dimerization domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.

Claims (11)

1. A monoclonal antibody that specifically binds to Notch3, wherein the antibody specifically binds to a conformational epitope of a Notch3 fragment consisting of amino acids 1378-1640 of SEQ ID NO:1, and wherein the antibody inhibits Notch3 signaling.

2. The antibody of claim 1 , wherein the antibody binds to amino acid residues in the LIN12 domain (SEQ ID NO:9) and the dimerization domain (SEQ ID NO:18).

3. The antibody of claim 1 , wherein the antibody comprises a variable heavy (“VH”) chain region comprising CDR-H1 of SEQ ID NO:32, CDR-H2 of SEQ ID NO:33, and CDR-H3 of SEQ ID NO:34, and a variable light (“VL”) chain region comprising CDR-L1 of SEQ ID NO:35, CDR-L2 of SEQ ID NO:36, and CDR-L3 of SEQ ID NO:37.

4. The antibody of claim 3 , wherein the VH chain region comprises SEQ ID NO:2, and the VL chain region comprises SEQ ID NO:3.

5. A humanized form of the antibody of claim 4 , wherein the humanized form specifically binds to a conformational epitope of a Notch3 fragment consisting of amino acids 1378-1640 of SEQ ID NO:1.

6. The antibody of claim 1 , wherein the antibody comprises a VH chain region comprising CDR-H1 of SEQ ID NO:38; CDR-H2 of SEQ ID NO:39, and CDR-H3 of SEQ ID NO:40, and a VL chain region comprising CDR-L1 of SEQ ID NO:41; CDR-L2 of SEQ ID NO:42, and CDR-L3 of SEQ ID NO:43.

7. The antibody of claim 6 , wherein the VH chain region comprises SEQ ID NO:4, and the VL chain region comprises SEQ ID NO:5.

8. A humanized form of the antibody of claim 7 , wherein the humanized form specifically binds to a conformational epitope of a Notch3 fragment consisting of amino acids 1378-1640 of SEQ ID NO:1.

9. The antibody of claim 1 , which is an antigen-binding antibody fragment.

10. The antibody of claim 1 , which is a human, humanized, or chimeric antibody.

11. The antibody of claim 1 , further comprising a label.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2008
From: FUNG, SEK CHUNG; LI, KANG; LI, YUCHENG; SINGH, SANJAYA; ZHOU, BIN-BING STEPHEN
To: GENENTECH, INC.
Reel/Frame 021021/0784 →
Continuity (3)
Provisional Application 60879218 · Jan 6, 2007
Provisional Application 60875597 · Dec 18, 2006
Related Publication 20080226621A1 · Sep 18, 2008